In the U.S., cancer is the second (only to heart disease) leading cause of death. Entropy Limited has worked with the National Cancer Institute and a number of clinics, pharmaceutical companies and biomedical devices companies on problems of cancer detection, diagnosis, treatment and rehabilitation.  For some of these organizations, the Entropy Limited analysis indicated the need for and insight into reorienting product capabilities and claims.  In addition to providing data validation and data analysis services, Entropy personnel have participated in redesigning biomedical instrumentation, rewriting product claims and reconfiguring diagnostic analyses.

In the area of tumor markers, Entropy Limited's technology offers a unique capability for identifying those diagnostic tests that increase the statistical performance of index tests in specific disease settings.  Ancillary tests are profiled that, when used in combination with the currently considered index tests, significantly improve performance. This can be done even when the number of candidate markers is large and the amount of combination test data is limited.

Breast Cancer Diagnosis

For Biofield Corp., Entropy Limited conducted instrumentation noise analysis and statistical pattern recognition modeling in the development of procedures for assessing the likelihood of breast cancer based on a new technology for making comparative passive electropotential measurements.

Cervical Cancer Detection

For Lifespex, Inc., EL developed image-processing software to perform the tissue characterization function of cervical tissue fluorescence spectroscopy, a non-invasive optical technology for detecting cervical cancer and pre-cancerous lesions.

Prostate Cancer Detection

For Chiron Diagnostics Corp., Entropy Limited identified patterns in laboratory measurements and related patient data. These patterns enhance the utility of PSA information in determining the likelihood of prostrate cancer.

Cancer Survival Patterns

In cooperation with Duke University Medical Center and the Southeastern Cancer Study Group, EL identified statistical survival patterns for lymphoma, chronic granulocytic leukemia and prostatic cancers.  The features identified in these patterns were closely approximated almost a decade later by much larger, multi-institutional groups that developed what have come to be called International Prognostic Indices (IPIs).

Measures of Effectiveness of Integrated Cancer Rehabilitation Services

Under the support of the National Cancer Institute, through a subcontract from Harmarville Rehabilitation Center, Inc., Entropy Limited designed randomization protocols and analyzed over 400 items of information on each of 600 cancer patients in an evaluation of the effectiveness of integrated cancer rehabilitation services of the Center to identify patterns of rehabilitation success.

Tumor Markers

For GMP Companies, Inc.,  EL provided analysis of the diagnostic performance of a large group of potential tumor markers that had been assembled by an academic collaborator.

Chemotherapeautic Potential of Candidate Neoplastic Drugs: Structural Correlates of Activity

For the National Cancer Institute, under a subcontract from Arthur D. Little, Inc., Entropy Limited analyzed the chemical structure, physical and chemical properties, and other known features of several hundred compounds for their chemotherapeutic activity in retarding cancers and possible toxicity effects. EL developed a classification system that effectively prioritized the evaluation of compounds for likely anti-tumor/toxicity prior to animal testing, enhancing the performance of the overall screening process and permitting greater efficiency in resource allocation.

Patterns of Survival and Response to Therapy in Patients with Non-Hodgkin's Lymphoma

For the Southeastern Cancer Society Group, EL analyzed data bases on non-Hodgkin's lymphoma and identified patterns for both response to therapy and survival. These patterns provide a means of stratifying patients for subsequent clinical trials and permit more accurate prognoses to be made for presenting patients.


HOME   Back to Biomedical Technology